vTv Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTVT research report →
Companywww.vtvtherapeutics.com
vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.
- CEO
- Paul J. Sekhri
- IPO
- 2015
- Employees
- 23
- HQ
- High Point, NC, US
Price Chart
Valuation
- Market Cap
- $94.77M
- P/E
- 135.44
- P/S
- 2.57
- P/B
- 3.39
- EV/EBITDA
- 1.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -8.26%
- Net Margin
- 6.11%
- ROE
- 3.96%
- ROIC
- -3.31%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-26,974,000 · -46.11%
- EPS
- $-3.20 · 0.00%
- Op Income
- $-32,808,000
- FCF YoY
- 0.21%
Performance & Tape
- 52W High
- $44.00
- 52W Low
- $14.00
- 50D MA
- $35.67
- 200D MA
- $29.63
- Beta
- 0.26
- Avg Volume
- 58.66K
Get TickerSpark's AI analysis on VTVT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 17, 26 | Tung Michael Stephen | other | 44,969 |
| Feb 17, 26 | SEKHRI PAUL J | other | 140,000 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 983,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 877,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 106,000 |
| Sep 3, 25 | AKKARAJU SRINIVAS | other | 655,523 |
| Sep 3, 25 | AKKARAJU SRINIVAS | other | 655,523 |
| Sep 3, 25 | BAKER BROS. ADVISORS LP | other | 2,353,913 |
| Sep 3, 25 | BAKER BROS. ADVISORS LP | other | 2,400,605 |
| Sep 3, 25 | BAKER BROS. ADVISORS LP | other | 217,144 |
Our VTVT Coverage
We haven't published any research on VTVT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VTVT Report →